Clarification from Glenmark Pharmaceuticals

29 Jul 2015 Evaluate

With reference to the news article in Financial Express July 29, 2015 captioned ‘Glenmark Pharmas skin gel infringes patent, says US court’, Glenmark Pharmaceuticals has clarified that they confirm the decision has been passed by the U.S. Court. Challenges in Para-IV filings are a usual practice in U.S. and the said decision can be appealed against. The Company is not generating any revenues out of the said product and hence the court decision has no material impact on the Company.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

1540.70 -52.20 (-3.28%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.